Home phase
 

Keywords :   


Tag: phase

Onxeo S.A.: Phase II trial results of Validive presented at the ASCO Conference

2015-04-02 18:23:24| Logistics - Topix.net

Regulatory News: Onxeo S.A. , an innovative company specializing in the development of orphan oncology drugs, today announced that Validive phase II clinical trial results have been accepted for a poster presentation at the 2015 Annual Meeting of the American Society of Clinical Oncology . The ASCO annual meeting is a major event in the field of oncology that brings together 30,000 health professionals and updates on the major latest steps and results achieved in oncology worldwide.

Tags: the results presented trial

 

Phase 1 Issues Framework

2015-04-02 00:21:08| PortlandOnline

Draft Task Force recommendations PDF Document, 786kbCategory: Phase 1 Recommendations (March 31)

Tags: issues phase framework

 
 

Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302

2015-04-01 08:23:10| drugdiscoveryonline Home Page

Therapure Innovations, a division of Therapure Biopharma Inc., recently announces that the U.S. Food and Drug Administration (FDA) has given the company approval to proceed with a Phase 1 clinical trial of TBI 302, a targeted therapeutic for the treatment of liver cancer

Tags: trial phase approval cancer

 

Emmaus Life Sciences To Present Phase 3 Sickle Cell Disease Clinical Trial Data

2015-04-01 07:37:14| drugdiscoveryonline Home Page

Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases recently announced that data from the Company’s Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting

Tags: data life present cell

 

Baxter BioScience Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophilia A And B Patients With Inhibitors

2015-04-01 07:33:48| drugdiscoveryonline Home Page

Baxter International Inc. recently announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa (rFVIIa) treatment for people with hemophilia A or B who develop inhibitors

Tags: with results iii positive

 

Sites : [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] next »